Remove Engineering Remove Licensing Remove Marketing
article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

The lack of collaboration between biologists, chemists, engineers and data scientists represents a significant barrier. He holds a master’s degree from University of Salerno in political sciences and marketing. Compartmentalised teams struggle to fully leverage multimodality, leading to suboptimal solutions.

article thumbnail

From FinOps Bean Counting to Value Harvesting: The Rise of Unit Economics

Perficient: Drug Development

Real technology spend includes observability tools, containers, data platforms, SaaS licensing, AI/ML, and peripheral services, sometimes hand-waved away as shadow IT or just life as part of an unavoidable cost center. Are Finance, Product, and Engineering collaborating on goals, reporting, and forecasting?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Nobel Prize celebrates AI’s role in protein structure innovation

Drug Target Review

Its applications include studying disease pathology to develop targeted therapeutics, visualising enzymes that can decompose plastics, and engineering solutions to antibiotic resistance, among many others. Further, trade secrets offer no protection against independent discovery or reverse engineering by competitors.

article thumbnail

Spirulina’s role in shaping the future of preventative biologics

Drug Target Review

The antibiotic market has long faced significant barriers to innovation, with structural issues that make it difficult for new antibiotics to gain traction. As the demand for novel antibiotics remains limited due to the preference for cheaper generics, the market has struggled to incentivise much-needed breakthroughs.

article thumbnail

Royalty Pharma and Revolution Medicines Sign Funding Deals Worth Up to $2 Billion

The Pharma Data

Unlike earlier attempts to inhibit individual mutations such as KRAS G12C, daraxonrasib is engineered to have broader inhibitory activity across multiple RAS mutations. This aligns both parties’ interests toward long-term success in the market.

article thumbnail

FDA to ask Sarepta to stop shipping Duchenne gene therapy

BioPharma Drive: Drug Pricing

Published July 18, 2025 • Updated 3 hours ago Ned Pagliarulo Lead Editor post share post print email license The U.S. Alamy The Food and Drug Administration will ask Sarepta Therapeutics to halt all shipments of its marketed gene therapy for Duchenne muscular dystrophy, a source familiar with the matter confirmed to BioPharma Dive.

article thumbnail

Dyadic International Rebrands as Dyadic Applied BioSolutions

The Pharma Data

For years, the company was primarily known for licensing its C1 platform for the development of therapeutic biologics and vaccines. Our C1 and Dapibus™ production platforms remain the engines we expect to drive commercial execution. The rebranding reflects our top priority: to deliver high-value input proteins at commercial scale.”